Navigation Links
MedImmune Broadens Focus of Venture Capital Fund to Include New Therapeutic Areas
Date:1/7/2008

- Expands Staff to Continue Record of Investment Success -

GAITHERSBURG, Md., Jan. 7 /PRNewswire/ -- MedImmune, the operationally independent worldwide biologics unit of AstraZeneca plc (LSE: AZN.L, NYSE: AZN), today announced that its highly successful venture capital fund, MedImmune Ventures, will broaden its focus to include areas of strategic interest to both organizations by adding the therapeutic areas of cardiovascular and metabolic disease, pain and central nervous system disorders and gastrointestinal disease. Traditionally, MedImmune Ventures has focused its efforts on the areas of infectious disease, oncology and inflammatory disease. Since its inception in 2002, MedImmune Ventures has invested in 22 companies.

"We look forward to making meaningful investments in these additional therapeutic areas," said Edward T. Mathers, executive vice president, corporate development and venture, MedImmune. "Now that we are more fully aligned with AstraZeneca's core areas of interest, we are able to help both MedImmune and AstraZeneca to stay at the forefront of novel science with a direct window to the most innovative start-ups in the biotechnology industry."

Mr. Mathers and MedImmune President & CEO David M. Mott currently lead MedImmune Ventures. To accommodate the broader disease area focus, MedImmune Ventures has added Maggie Flanagan LeFlore, Ph.D. and Eva M. Jack as managing directors to its team of experts that oversee the assessment of all new investment opportunities. Previously, Dr. LeFlore was on assignment from AstraZeneca to the healthcare and life science venture investment team at Advent International, and Ms. Jack was director, business development at MedImmune. Also, Joseph L. Amprey, M.D., Ph.D. was promoted to managing director of MedImmune Ventures following the June 2007 retirement of its president, Wayne T. Hockmeyer, Ph.D. Franklin H. Top, M.D., who has been with MedImmune since 1988 and is the company's former m
'/>"/>

SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. MedImmune Announces Seven Key Promotions and New Hires
7. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
8. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
9. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
10. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
11. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... 2014 Texas Governor Rick Perry, ... A&M Health Science Center CEO Brett Giroir, M.D., ... and Human Services (HHS), State of Texas and ... influenza vaccine manufacturing facility in Bryan, Texas, which ... the Texas A&M Biocorridor – a rapidly evolving ...
(Date:9/18/2014)... DUBLIN , Sept. 18, 2014 ... the "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ ... report to their offering. The ... a CAGR of 22.7% from 2014 to 2019. Factors ... treatment, growing adoption of companion diagnostics by the pharmaceutical ...
(Date:9/18/2014)... SEATTLE , Sept. 18, 2014 /PRNewswire/ - Oncothyreon ... pricing of previously announced concurrent but separate underwritten offerings ... price to the public of $2.00 per share, for ... of its Series A Convertible Preferred Stock at a ... expected gross proceeds of $20 million. Each share of ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... was involved in the cloning of Dolly the sheep said ... coverage of embryonic stem cell research, which could be raising ... corner when they are at least a few years away. ... said news of the possibilities of human embryonic stem cell ...
... their best mind you, growing up was "Aftermath", an appropriate label ... 2006- Chicago. , ,As BIO 2006 - Chicago is still fresh ... the outcome, but so many others have already done so that ... more of the facts emerge (like the final attendance number). Suffice ...
... - A young company with a preventive solution to identity ... G. Steven Burrill Technology Business Plan Competition, but if area ... they better act quickly. , , Din and Newport ... plan. Khaja M. Din, president IPIC (Internet ...
Cached Biology Technology:Researchers say scientific reporting needs more perspective, less hype 2Researchers say scientific reporting needs more perspective, less hype 3BIO 2006 aftermath and a taste of bio-generics 2BIO 2006 aftermath and a taste of bio-generics 3BIO 2006 aftermath and a taste of bio-generics 4BIO 2006 aftermath and a taste of bio-generics 5BIO 2006 aftermath and a taste of bio-generics 6BIO 2006 aftermath and a taste of bio-generics 7BIO 2006 aftermath and a taste of bio-generics 8Winner of Burrill competition courted by North Carolina investors 2Winner of Burrill competition courted by North Carolina investors 3
(Date:9/19/2014)... study the unique bioelectric signaling system of the electric ... The OU researcher is working to understand how ... signals used to map the world around them. ... 500-600 discharges a second throughout their lives. The ... but necessary for survival. , "There is evidence that ...
(Date:9/19/2014)... , Sept. 19, 2014 Nxt-ID, Inc. (Nasdaq: ... company focused on the growing m-commerce market, updates the "Wocket in ... in the lightweight and light middleweight weight classes, Vinny Pazienza ... was announced that Game of Thrones actor Ciaran ... with Children star Katey Sagal have been cast ...
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
Breaking Biology News(10 mins):NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 2NXT-ID's Vinny Paz Celebrity Ad Wocket Update: Katey Sagal and Ciaran Hinds Attached to His Upcoming Movie 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... for detecting cocaine –?made with inexpensive, off-the-shelf electronics –?has ... University of California, Santa Barbara. Two local high school ... The potential applications of the sensor are far-reaching and ... high school students made their own sensors and collected ...
... that highly active antiretroviral therapy (HAART) is very cost-effective, ... shows that reimbursement to physicians treating patients with HIV ... study findings are reported in the April 1 issue ... HAART has led to dramatic decreases in illness and ...
... the ends of bones where they meet in a ... can lead to degenerative disease. Treatments and experimental approaches ... but currently there is no method to fully restore ... delivery of therapeutic proteins to the injured site is ...
Cached Biology News:Portable cocaine sensor developed at UC Santa Barbara 2Portable cocaine sensor developed at UC Santa Barbara 3Study shows AIDS drugs cost-effective, care underfunded 2Study shows AIDS drugs cost-effective, care underfunded 3Stem cells from muscles can repair cartilage 2Stem cells from muscles can repair cartilage 3
Polyclonal Antibody to HADHB...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
A431 cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: